Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 product SHR1905, a thymic stromal lymphopoietin (TSLP)-targeted monoclonal antibody (mAb). The product is intended for the treatment of asthma in adolescents aged 12-17.
SHR1905 was the focus of an out-licensing deal with U.S. biotech firm One Bio Inc., which was valued at over USD 1 billion in August of the previous year. A similar product, Tezspire (tezepelumab), co-developed by AstraZeneca/MedImmune and Amgen, received marketing approval in the United States in December 2021.- Flcube.com
